Lundbeck parks Alzheimer's drug hope as there is no evidence it works

Pharmaceutical firm Lundbeck still sees opportunities to treat Alzheimer’s, but believes patience is a virtue. ”Jumping blindly into this area without any clear evidence is really not good for business,” says Head of R&D Johan Luthman.

Johan Luthman, head of research and development at Lundbeck | Photo: PR / Lundbeck

Pharmaceutical firm Lundbeck is hoping to avoid the costly blunders of the past, and has therefore halted one of its drug hopes meant to treat the feared brain condition known as Alzheimer’s disease. At least for the time being.

”We’ve parked Lu AF97908 because we don’t have a single piece of evidence in the world that such an antibody works,” says Johan Luthman, head of research and development at Lundbeck.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs